We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
Read MoreHide Full Article
With a market capitalization of approximately $868.7 million, AngioDynamics, Inc (ANGO - Free Report) is expected to benefit from expanding product portfolio, international market expansion and cost-saving initiatives. These factors indicate considerable growth opportunities in the long run.
However, softness in the company’s Venous Insufficiency business and PICC product lines is a concern.
The stock has a Zacks Rank #3 (Hold). Here we take a quick look at the primary factors that have been plaguing AngioDynamics and discuss the prospects that ensure the stock’s near-term recovery.
What’s Deterring AngioDynamics?
AngioDynamics’ Venous Insufficiency business has been sluggish as its largest customer discontinued the exclusive use of EVLT (Endovenous Laser System) products.
As a result of this, AngioDynamics’core Peripheral Vascular business has also been slow. The company renamed the Peripheral Vascular business to Vascular Interventions.
Per management, growth in ports and dialysis products was significantly offset by declines in PICCs.
Why Should You Hold AngioDynamics?
AngioDynamics is a leading provider of minimally invasive medical devices used for vascular access, surgery, peripheral vascular disease and oncology. The company’s product lines include ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products as well as venous products.
The company continues to enjoy healthy demand for the coveted NanoKnife system for treating tumors. Higher penetration of the device contributed to revenues in the company’s Oncology division. In fact, the recent regulatory approval of VOLTA, a radiofrequency ablation device in Japan, is also a significant positive in our view. The company is already trying to expand commercial opportunities. Besides Germany and Denmark, the company is also looking forward to achieve the same in the rest of Europe and the United Kingdom.
Shares of AngioDynamics have outperformed the industry in a year's time. Notably, the company’s shares have rallied 30.7%, against the industry's decline of 6.6%. The current level is also higher than the S&P 500 index's rise of 16.2%.
Which Way are the Estimates Treading?
For the current quarter, the Zacks Consensus Estimate for earnings is pegged at 18 cents, reflecting growth of 50% on a year-over-year basis. The same for the revenues is pegged at $83.4 million, reflecting a decline of 2.4% year over year.
For 2018, the Zacks Consensus Estimate for revenues is pegged at $347.6 million, reflecting growth of 1% year over year. The same for adjusted earnings for 2018 is pegged at 86 cents, reflecting an increase of 16.2% year over year.
A few better-ranked stocks in the broader medical space are athenahealth , Intuitive Surgical (ISRG - Free Report) and Veeva Systems (VEEV - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock flaunts a Zacks Rank #1.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock sports a Zacks Rank #1.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
With a market capitalization of approximately $868.7 million, AngioDynamics, Inc (ANGO - Free Report) is expected to benefit from expanding product portfolio, international market expansion and cost-saving initiatives. These factors indicate considerable growth opportunities in the long run.
However, softness in the company’s Venous Insufficiency business and PICC product lines is a concern.
The stock has a Zacks Rank #3 (Hold). Here we take a quick look at the primary factors that have been plaguing AngioDynamics and discuss the prospects that ensure the stock’s near-term recovery.
What’s Deterring AngioDynamics?
AngioDynamics’ Venous Insufficiency business has been sluggish as its largest customer discontinued the exclusive use of EVLT (Endovenous Laser System) products.
As a result of this, AngioDynamics’core Peripheral Vascular business has also been slow. The company renamed the Peripheral Vascular business to Vascular Interventions.
Per management, growth in ports and dialysis products was significantly offset by declines in PICCs.
Why Should You Hold AngioDynamics?
AngioDynamics is a leading provider of minimally invasive medical devices used for vascular access, surgery, peripheral vascular disease and oncology. The company’s product lines include ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products as well as venous products.
The company continues to enjoy healthy demand for the coveted NanoKnife system for treating tumors. Higher penetration of the device contributed to revenues in the company’s Oncology division. In fact, the recent regulatory approval of VOLTA, a radiofrequency ablation device in Japan, is also a significant positive in our view. The company is already trying to expand commercial opportunities. Besides Germany and Denmark, the company is also looking forward to achieve the same in the rest of Europe and the United Kingdom.
Shares of AngioDynamics have outperformed the industry in a year's time. Notably, the company’s shares have rallied 30.7%, against the industry's decline of 6.6%. The current level is also higher than the S&P 500 index's rise of 16.2%.
Which Way are the Estimates Treading?
For the current quarter, the Zacks Consensus Estimate for earnings is pegged at 18 cents, reflecting growth of 50% on a year-over-year basis. The same for the revenues is pegged at $83.4 million, reflecting a decline of 2.4% year over year.
For 2018, the Zacks Consensus Estimate for revenues is pegged at $347.6 million, reflecting growth of 1% year over year. The same for adjusted earnings for 2018 is pegged at 86 cents, reflecting an increase of 16.2% year over year.
AngioDynamics, Inc. Price and Consensus
AngioDynamics, Inc. Price and Consensus | AngioDynamics, Inc. Quote
Key Picks
A few better-ranked stocks in the broader medical space are athenahealth , Intuitive Surgical (ISRG - Free Report) and Veeva Systems (VEEV - Free Report) .
athenahealth has a long-term expected earnings growth rate of 17.6%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock flaunts a Zacks Rank #1.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock sports a Zacks Rank #1.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>